| Accession |
PRJCA012612 |
| Title |
An open, single-arm, single-center, parallel cohort study on the exploration of neoadjuvant stereotactic radiotherapy combined with radiotherapy for TNBC and HR+/HER2- breast cancer |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker,Genetic data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the efficacy and safety of SHR1316 combined with stereotactic radiotherapy followed by SHR1316 combined with chemotherapy as neoadjuvant therapy for TNBC Sex;To evaluate the efficacy and safety of stereotactic radiotherapy followed by SHR6390 and AI in the neoadjuvant treatment of HR+/HER2- breast cancer. |
| Sample scope |
Multiisolate |
| Release date |
2022-10-19 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2022-10-19 |
